Применение ницерголина (Сермиона) в комплексной терапии деменций позднего возраста в амбулаторой практике

Aim: to conduct an observational study to assess the experience of the clinical using of modern drug therapy of dementia in aged and to study the effectiveness and safety of the Sermione using in the complex pathogenetic therapy of the dementia in the outpatient gerontopsychiatric practice.Material and methods: in the non-sampling study were included 85 outpatients (29 men and 56 women; median age 72 years) from Alzheimer's disease and associated disorders Department of FSBSI «Mental health research centre» from 2014 to 2016. The patients were taken Sermion (nicergolin) in the complex pathogenetic therapy of the dementia: 46 patients were treated with the acetylcho- linesterase inhibitors (AChEI), 23 patients - memantine and 16 patients were treated with AChEI and memantine (12 cases of early onset of AD, 19 cases with late onset of AD, 36 cases of mixed dementia) as well as for vascular dementia (18 cases). The clinical method and psychometric scales (MMSE, CDT, CGI) used for the diagnosis and assessment of the results Sermion orally treatment in a dose of 30 mg per day. Sermion is a part of the complex dementia therapy. A total duration of Sermion administration treatment was 3 months. Results: the Sermion treated patients have moderate and minimal improvement in 33.3% of EOAD, at 42,1% with LOAD, in 61,1%of mixed dementia cases and in 88.9% vascular dementia cases according to the CGI scale. The clinical improvement was confirmed the data of the psychometric assessment, in particular, with a 1-point increase in MMSE score in Alzheimer’s disease and with 2-points increase in MMSE score in mixed and vascular dementia patients. It is important to note that the improvement or stabilization of the condition in Sermion treated patients was marked with different severity degrees of dementia. We observed the cognitive functioningпсихиатрия 1`2017improving, the reduction of psychopathological symptoms, primarily depressive and behavioral disorders, and confusion. During the Sermion treatment was not observed negative side effects.Conclusions: the use of orally form Sermion is effective and safe in the complex pathogenetic therapy of the dementia Alzheimer's disease, mixed dementia and vascular dementia (AChEI and memantine). The Sermion appointment in the complex antidementia therapy was validated with different severity of dementia and with the non-cognitive neuropsychiatric disorders.

поздний возраст, деменция, болезнь Альцгеймера, смешанная деменция, сосудистая деменция, лечение, Сермион, old age, dementia, Alzheimer’s disease, mixed dementia, vascular dementia, treatment, Sermion

1. Leon A.C. Evaluation of psychiatric interventions in an ob- servational study: issues in design and analysis. Dialogues in Clin Neurosci. 2011;13,2:191-198

2. Möller H.-J. Effectiveness studies: advantages and disadvan- tages. Dialogues in Clin. Neurosci. 2011;13,2:199-207

3. Patsopoulos N.F. A pragmatic view on pragmatic trials. Dia- logues in Clin. Neurosci. 2011;13,2:217-224

4. Fioravanti M. et al. A systematic review and meta-analysis as- sessing adverse event profile and tolerability of nicergoline. BMJ Open. 2014;4,№7:e005090

5. Fioravanti M., Flicker L. Nicergoline for dementia and oth- er age associated forms of cognitive impairment. Cochrane Database of Systematic Reviews. ed. Fioravanti M. Chichester, UK: John Wiley & Sons, Ltd, 2001;4:CD003159

6. Winblad B. et al. Therapeutic Use of Nicergoline . Clin. Drug Investig. 2008;28,№9:533-552

7. Winblad B. et al. Nicergoline in Dementia. CNS Drugs. Spring- er International Publishing. 2000;14,№4:267-287

8. Matsuoka Y. et al. Inhibitory action of nicergoline and its me- tabolites on acetylcholinesterase activity in rats and mouse brain. Adv. Behav. Biol. B. 1990;38:415-419

9. Nishida A. et al. Nicergoline enhances glutamate uptake via glutamate transporters in rat cortical synaptosomes. Biol. Pharm. Bull. 2004;27,№6:817-820

10. Yoshida T., Tanaka M., Okamoto K. Inhibitory effect of nicer- goline on superoxide generation by activated rat microglias measured using a simple chemiluminescence method. Neu- rosci. Lett. 2001;297,№1:5-8

11. Asai S. et al. Nicergoline enhances glutamate re-uptake and protects against brain damage in rat global brain ischemia. Eur. J. Pharmacol. 1999;383,№3:267-274

12. Mizuno T. et al. Protective effects of nicergoline against neu- ronal cell death induced by activated microglia and astro- cytes. Brain Res. 2005;1066,№1:78-85

13. Vairetti M. et al. Haloperidol-induced changes in glutathione and energy metabolism: Effect of nicergoline. Eur. J. Pharma- col. 1999;367,№1:67-72

14. Vairetti M. et al. Nicergoline reverts haloperidol-induced loss of detoxifying-enzyme activity. Eur. J. Pharmacol. 2004;505,№1-3:121-125

15. Carfagna N. et al. Modulation of phosphoinositide turn- over by chronic nicergoline in rat brain. Neurosci. Lett. 1996;209:189-192

16. Cedazo-Minguez a et al. Nicergoline stimulates protein ki- nase C mediated alpha-secretase processing of the amyloid 58 precursor protein in cultured human neuroblastoma SH- SY5Y cells. Neurochem. Int. 1999;35,№4:307-315

17. Caraci F. et al. Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against β-amyloid toxicity. Brain Res. 2005;1047,№1:30-37

18. Walford T., Musa F.I., Harper A.G.S. Nicergoline inhibits hu- man platelet Ca 2+ signalling through triggering a microtu- bule-dependent reorganization of the platelet ultrastruc- ture. Br. J. Pharmacol. 2016;173,№1:234-247

19. Giardino L. et al. Neuroprotection and aging of the cholin- ergic system: a role for the ergoline derivative nicergoline (Sermion). Neuroscience. 2002;109,№3:487-497

20. Nishio T. et al. Repeated injections of nicergoline increase the nerve growth factor level in the aged rat brain. Jpn. J. Pharmacol. 1998;76,№3:321-323

21. Carfagna N. et al. Modulation of hippocampal ACh release by chronic nicergoline treatment in freely moving young and aged rats. Neurosci. Lett. 1995;197,№ 3:195-198

22. Moretti A. et al. Effect of ergolines on neurotransmitter systems in the rat brain. Arch. Int. Pharmacodyn. Ther. Vol. 294:33-45

23. Руководство по гериатрической психиатрии. Под ред. С.И. Гавриловой. М.: Пульс; 2011:113-129

24. Arcari G., Dorigotli L., Fregnan G.B. et al. Vasodilating and al- pha-receptor blocking activity of a new ergoline derivative. Br. J. Pharmacol. 1968;34(3):700

25. Alvarez-Guerra M., Bertholom N., Garay R.P. Selective block- ade by nicergoline of vascular responses elicited by stimula- tion of alphaiA-adrenoceptor subtype in the rat. Fundam. Clin. Pharmacol. 1999;13(1):50-58. doi:10.1111/j.1472-8206.1999. tb00320.x

26. Philippon B.L., Thivolle P., Berger M. [Nicergoline and steal effect in favor of zones of hypoperfusion in cerebral isch- emic accidents]. Rev. d’électroencéphalographie Neurophysi- ol. Clin. 1982;12,№4:361-366

27. Mirzoyan R.S., Ganshina T.S., Pukhalskaya T.G., Volobue- va T.I., Vedernikov Y.P., Dikova M., Nikolova M., Nikolov R. Effects of nicergoline in experimental models related to pathogenesis of migraine. Methods Find. Exp. Clin. Pharma- col. 1989;11(11):671-676

28. Le Poncin-Lafitte M., Grosdemouge C., Duterte D. et al. Simultaneous study of haemodynamic, metabolic and be- havioural sequelae in a model of cerebral ischaemia in aged rats: effects of nicergoline. Gerontology. 1984;30(2):109-119

29. Pogliani E., Volpe A.D., Ferrari R., Recalcati P., Praga C. Inhi- bition of human platelet aggregation by oral administra- tion of nicergoline: a double-blind study. Farmaco Lprat. J. 1975;30(12):630-640

30. Saletu B., Garg A., Shoeb A. Safety of nicergoline as an agent for management of cognitive function disorders. Biomed Res. Int. Hindawi Publishing Corporation. 2014;2014:610103

31. Miccheli A., Puccetti C., Capuani G. et al. GIucose entry in neuronal and astrocytic intermediary metabolism of aged rats: a study of the effects of nicergoline treatment by 13C NMR spectroscopy. Brain Res. 2003;966(1):116-125. doi:10.1016/S0006-8993(02)04217-8

32. Nicergolin (Sermion). A Product Monograph. ADIS Interna- tional. Milano. 1996:56

33. Battaglia A., Bruni G., Ardia A., Sacchetti G. Nicergoline in mild to moderate dementia: a multicenter, double-blind, placebo-controlled study. J. Am. Geriatr. Soc. 1989;37(4):295- 302. doi:10.1111/j.1532-5415.1989.tb05494.x

34. Nappi G., Bono G., Merlo P. et al. Long-term nicergoline treatment of mild to moderate senile dementia: results of a multi-centre, double-blind, placebocontrolled study. Clin. Drug Invest. 1997;13(6):308-316. doi:10.2165/00044011- 199713060-00003

35. Радзивил Г.Г., Герасимов Н.П., Селезнева Н.Д., Красноперова М.Г. Состояние центральной гемодинамики у больных с деменцией альцгеймеровского типа в процессе терапии ницерголином. В кн. Болезнь Альцгеймера и старение: от нейробиологии к терапии. М.; 1999:112-114